# David A. Reardon

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-a-reardon/

## Facts

| Field | Value |
| --- | --- |
| Citations | 63,984 |
| Field | Glioma Diagnosis and Treatment |
| h-index | 120 |
| i10-index | 456 |
| Last Known Institution | Harvard University |
| OpenAlex ID | https://openalex.org/A5059965175 |
| ORCID iD | https://orcid.org/0000-0001-6674-0157 |
| Works | 1,228 |

## Researcher papers

- [Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma](https://scholariq.org/papers/neoadjuvant-anti-pd-1-immunotherapy-promotes-a-survival-benefit-with/)
- [Immunotherapy response assessment in neuro-oncology: a report of the RANO working group](https://scholariq.org/papers/immunotherapy-response-assessment-in-neuro-oncology-a-report-of-the-rano-working/)
- [Mechanisms and therapeutic implications of hypermutation in gliomas](https://scholariq.org/papers/mechanisms-and-therapeutic-implications-of-hypermutation-in-gliomas/)
- [Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors](https://scholariq.org/papers/differential-sensitivity-of-glioma-versus-lung-cancer-specific-egfr-mutations-to/)
- [Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma](https://scholariq.org/papers/randomized-phase-ii-and-biomarker-study-of-pembrolizumab-plus-bevacizumab-versus/)

## Researcher topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)

## Researcher university

- [Harvard University](https://scholariq.org/institutions/harvard-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.